Novo and Lilly Race for Dominance in the GLP-1 Pill Market

Novo Nordisk reported that prescriptions for its Wegovy pill have exceeded 3 million since its U.S. launch five months ago. CEO Mike Doustdar emphasized that growth remains robust despite Eli Lilly entering the market with its own GLP-1 pill, Foundayo, in April. While Lilly has not disclosed a precise current figure, CEO Dave Ricks noted that prescription volume is markedly higher than the 20,000 reported during the company's first-quarter earnings release six weeks ago.

The industry rivalry is set to intensify this July when Medicare begins covering GLP-1 drugs for weight loss, capping costs for seniors at $50 per month. Previously, beneficiaries faced significant out-of-pocket expenses that often reached hundreds of dollars. As both companies pivot their marketing strategies toward this new patient demographic, they are balancing the promotion of daily oral medications against their established weekly injectable therapies.